Altimmune, Inc. (ALT) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

Earnings Reports

• Altimmune (ALT) Q1 2026: $535M Cash Runway Secured, Phase 3 MASH Launch Targets 2029 Readout
  May 13, 2026
• Altimmune (ALT) Q4 2025: $340M Cash Secured to Fund Phase III MASH Program Launch
  March 05, 2026
• Altimmune (ALT) Q3 2025: Cash Surges 60% as Pemvidutide Readies for Phase III Pivot
  November 06, 2025
• Altimmune (ALT) Q2 2025: $183M Cash Bolsters Phase 3 MASH Readiness Amid 59% Resolution Signal
  August 12, 2025
• Altimmune (ALT) Q1 2025: $100M Credit Facility Extends Runway as MASH Phase 2b Readout Nears
  July 06, 2025
• Altimmune (ALT) Q3 2024: $139M Cash Runway Extends Through 2026 as Phase 3 Obesity Program Secures FDA Alignment
  November 12, 2024
• Altimmune (ALT) Q2 2024: R&D Spend Rises 59% as Pembidutide Differentiation Narrative Intensifies
  August 08, 2024
• Altimmune (ALT) Q1 2024: R&D Spend Rises 25% as Phase 3 Obesity Program Readies for Expansion
  May 09, 2024
• Altimmune (ALT) Q4 2023: 74% Fat Loss Ratio, Differentiates Pembidutide in Obesity and MASH Pipeline
  March 27, 2024

Browse all companies